BiTE efficacy is in part limited by specific tumor cell phenotypes, such as the expression of sialophorin which limits T cell to tumor cell adhesion (89), and by similar side effects of CRS and neurotoxicity observed in CAR Therapy (90, 91). Here, SPN is linked to neoplasm.